Gilead to present new data on PBC, viral hepatitis at EASL 2026

Gilead (GILD) Sciences will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi, known as Lyvdelzi in the European Union. Analyses from the Phase 3 RESPONSE trial will evaluate efficacy and safety in participants with risk factors for disease progress, including elevated liver stiffness and metabolic syndrome. Interim data from the Phase 3 ASSURE study will assess the relationship between biochemical response and liver stiffness trends over 36 months, including outcomes in individuals with alkaline phosphatase levels between 1 to 1.67x the upper limit of normal. Together these data provide a multidimensional view of Livdelzi’s efficacy, safety and durability across a broad PBC population. Livdelzi is a first-in-class delpar indicated for the treatment of PBC to be used in combination with ursodeoxycholic acid for those with an inadequate response to UDCA, or as monotherapy for patients unable to tolerate UDCA. “Primary biliary cholangitis is a chronic, progressive disease where reducing disease activity is critical to improving long-term outcomes. Minimizing impact on quality of life is also key for people living with PBC,” said Swati Tole, MD, MS, Senior Vice President, Clinical Development, Inflammation at Gilead Sciences. “At EASL, we are sharing data that further define Livdelzi’s potential to address both disease activity and symptoms such as pruritus.”